BioSpace News Archive

Rheos Medicines today announced it will present two poster presentations at ACR Convergence 2021, the annual meeting of the American College of Rheumatology which will be held virtually from November 3-9, 2021.

Berry Oncology, a Chinese oncology genomic testing company, was invited to the inaugural International Biopharma Industry Week in Shanghai (IBIWS) running from October 11-14

VBI Vaccines Announces Publication of Results from Pivotal Phase 3 Study, CONSTANT, of VBI’s Prophylactic 3-Antigen Hepatitis B Vaccine Candidate in The Journal of the American Medical Association Network Open.

TC BioPharm LTD, a clinical stage biotechnology company developing an allogeneic gamma-delta T cell platform, today announces launch of a Phase I/II trial in COVID-19 infected patients in the UK.

SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced presentations of a pooled data analysis from its successful VANISH clinical development program during two October medical meetings.

Tesis Labs announced today the addition of John Shufeldt , M.D., to its company board of directors.

CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced that data from its CB4211 Phase 1a/1b clinical study have been selected for presentation during the late-breaking poster session at The American Association for the Study of Liver Diseases (AASLD) Annual Meeting (The Liver Meeting® 2021).

Sorrento Therapeutics, Inc. (NASDAQ: SRNE, “Sorrento”) announced that the company has received FDA clearance to proceed with a global Phase 2 clinical study of resiniferatoxin (RTX), entitled “A Multicenter, Phase 2 Study to Assess the Safety and Efficacy of Epidural Resiniferatoxin for the Treatment of Intractable Pain Associated with Advanced Cancer”.

APEIRON Biologics AG, a privately held biotechnology company developing novel immunotherapies for cancer and respiratory diseases, today announced the start of a company sponsored Phase 1 trial for inhalation of APN01.

Curative Biotechnology, Inc. announced today that Dr. Catherine Sohn has joined the Company as a Special Advisor to the Board of Directors and the CEO.